Joseph A ODonoghue
Overview
Explore the profile of Joseph A ODonoghue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandit-Taskar N, ODonoghue J, Chetty D, Max S, Wanik D, Ilovich O, et al.
J Nucl Med
. 2024 May;
65(7):1051-1056.
PMID: 38782459
Despite the inclusion of multiple agents within the prostate cancer treatment landscape, new treatment options are needed to address the unmet need for patients with metastatic castration-resistant prostate cancer (mCRPC)....
2.
Yeh R, ODonoghue J, Jayaprakasam V, Mauguen A, Min R, Park S, et al.
J Nucl Med
. 2024 Jan;
65(3):386-393.
PMID: 38272704
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used to radiolabel these antibodies...
3.
Laccetti A, Bodei L, ODonoghue J, Weber W, Morris M
Clin Nucl Med
. 2023 Oct;
48(11):937-944.
PMID: 37812518
Purpose: 131I-MIP-1095 is a targeted radiotherapeutic that contains 131I, a β-particle emitter, and MIP-1095, a urea-based ligand for prostate-specific membrane antigen. We report the first phase 1, dose-escalation study of...
4.
Grkovski M, ODonoghue J, Imber B, Andl G, Tu C, Lafontaine D, et al.
J Nucl Med
. 2023 Aug;
64(11):1779-1787.
PMID: 37652541
A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility of combining [Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic castration-sensitive prostate...
5.
Lumish M, Maron S, Paroder V, Chou J, Capanu M, Philemond S, et al.
J Nucl Med
. 2022 Nov;
64(5):724-730.
PMID: 36418168
Variations in human epidermal growth factor receptor 2 (HER2) expression between the primary tumor and metastases may contribute to drug resistance in HER2-positive (HER2+) metastatic esophagogastric cancer (mEGC). Zr-trastuzumab PET...
6.
Krebs S, Grommes C, McDevitt M, Carlin S, ODonoghue J, Graham M, et al.
Eur J Nucl Med Mol Imaging
. 2022 Mar;
49(6):2102.
PMID: 35266033
No abstract available.
7.
Krebs S, Grommes C, McDevitt M, Carlin S, ODonoghue J, Graham M, et al.
Eur J Nucl Med Mol Imaging
. 2021 Sep;
49(2):783-785.
PMID: 34498111
No abstract available.
8.
Kirchner J, ODonoghue J, Becker A, Ulaner G
EJNMMI Phys
. 2021 Jan;
8(1):6.
PMID: 33469848
Purpose: The aim of this study was to evaluate the use of a Bayesian penalized likelihood reconstruction algorithm (Q.Clear) for Zr-immunoPET image reconstruction and its potential to improve image quality...
9.
Konik A, ODonoghue J, Wahl R, Graham M, Van Den Abbeele A
Semin Radiat Oncol
. 2020 Nov;
31(1):28-36.
PMID: 33246633
Theranostics is a precision medicine discipline that integrates diagnostic nuclear medicine imaging with radionuclide therapy in a manner that provides both a tumor phenotype and personalized therapy to patients with...
10.
Krebs S, ODonoghue J, Biegel E, Beattie B, Reidy D, Lyashchenko S, et al.
Eur J Nucl Med Mol Imaging
. 2020 May;
47(13):3047-3057.
PMID: 32378020
Purpose: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of Ga-DOTA-JR11 and...